Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,32800518,overall un,"The overall unconfirmed response rate was 84%, and the confirmed complete response rate was 44%.",Phase 2 Study of Iodine-131 Tositumomab Plus Chemotherapy in Patients With Previously Untreated Mantle-Cell Lymphoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32800518/),%,84,126296,DB00081,Tositumomab
,32800518,confirmed complete response rate,"The overall unconfirmed response rate was 84%, and the confirmed complete response rate was 44%.",Phase 2 Study of Iodine-131 Tositumomab Plus Chemotherapy in Patients With Previously Untreated Mantle-Cell Lymphoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32800518/),%,44,126297,DB00081,Tositumomab
,32800518,progression free-survival,The median progression free-survival was 27.6 months.,Phase 2 Study of Iodine-131 Tositumomab Plus Chemotherapy in Patients With Previously Untreated Mantle-Cell Lymphoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32800518/),month,27.6,126298,DB00081,Tositumomab
,32800518,total body residence time,The median total body residence time was 94.5 hours.,Phase 2 Study of Iodine-131 Tositumomab Plus Chemotherapy in Patients With Previously Untreated Mantle-Cell Lymphoma. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32800518/),h,94.5,126299,DB00081,Tositumomab
,15154740,biological half-life,"In addition, the half-life of 90Y matches the in vivo biological half-life of the monoclonal antibody (64 h), with negligible excretion of 90Y in urine.",The role of nuclear medicine in the treatment of non-Hodgkin's lymphoma (NHL). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15154740/),h,64,156442,DB00081,Tositumomab
